Browse Studies — Arctuva

Phase 1

A Phase 1, Randomized, Single-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of Orally Administered LY5625575 in Healthy Participants, Including Japanese and Chinese Populations, and in Participants With Elevated C-Reactive Protein

The main purpose of this study is to evaluate the safety and tolerability of LY5625575 in healthy participants (including Japanese and Chinese) and in particip…

Healthy VolunteersC-Reactive Protein

Estimated

~$10 – $7,500